Join Foundation Medicine in Chicago, Illinois, May 31-June 4, Booth #22031
Meet with our team
Posters and Presentations
Exploiting circulating tumor DNA (ctDNA) to intensify the adjuvant or post-adjuvant treatment of stage III and high-risk stage II resected colon cancer patients: the ERASE-CRC project
First author
Chiara Cremolini
Collaborating Institution
University of Pisa, Italy
DO:
Colorectal
Abstract:
TPS3644 | Poster
Utility of circulating tumor DNA (ctDNA) to inform treatment of patients with metastatic breast cancer
First author:
Laura Linville
Collaborating Institution:
Johns Hopkins University School of Medicine, Baltimore, MD
DO:
Breast
Abstract:
1042 | Poster
Prognostic value of baseline cell-free DNA (cfDNA) tumor fraction (TF) in metastatic hormone-sensitive prostate cancer (mHSPC)
First author:
Charles B. Nguyen
Collaborating Institution:
Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA
DO:
Prostate
Abstract:
5085 | Poster
Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate
First author:
Arun Azad
Collaborating Institution:
Peter MacCallum Cancer Centre, Department of Medical Oncology
DO:
Prostate
Abstract:
5020 | Poster
BRCA1/2 Reversion Mutations in Advanced Prostate Cancer in the Absence of Prior PARP inhibitor (PARPi) Therapy
First author:
Douglas Lin
Institution:
Foundation Medicine, Inc.
DO:
Prostate
Abstract:
5056 | Poster
Preliminary Results of the Lung Cancer Mutation Consortium - LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer (LEADER) Screening Trial
First author:
Jamie Chaft
Collaborating Institution:
Baylor College of Medicine
DO:
Lung
Abstract:
8068 | Poster
Pathological complete response (pCR) association with a novel HRD signature (HRDsig) in triple-negative breast cancer (TNBC) patients receiving neoadjuvant therapy (Tx)
First author:
Tanya Gupta
Collaborating Institution:
Stanford University, Stanford, CA
DO:
Breast
Abstract:
591 | Poster
Genomic alterations (GA) in ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) patients (pts) with metastatic breast cancer (MBC): co-occurrence and prevalence along treatment course
First author:
Manali Bhave
Collaborating Institution:
Emory University, Atlanta, GA
DO:
Breast
Abstract:
1060 | Poster
Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors
First author:
Dazhi Liu
Collaborating Institution:
Memorial Sloan Kettering Cancer Center, New York, NY
DO:
Pan-tumor
Abstract:
3129
Impact of HER2 Low Status on Genomic Signatures in Triple Negative Breast Cancer (TNBC)
First author:
Melissa Taylor
Institution:
Foundation Medicine, Inc.
DO:
Breast
Abstract:
1092 | Poster
Nature and Distribution of Methyl thioadenosine phosphorylase (MTAP) Genomic Loss in Human Tumors
First author:
A Necchi
Collaborating Institution:
San Raffaele Hospital and Scientific Institute, Italy
DO:
Pan-tumor
Abstract:
3067 | Poster
The Increasing Frequency of Inactivating STK11 Mutations in Lung Adenocarcinomas (LA) over a Ten-Year Period likely Indicates the Development of Acquired Resistance to Immune Checkpoint Inhibitor (ICPI) Based Treatments
First author:
Deevyashali Parekh
Institution:
Foundation Medicine, Inc.
DO:
Lung
Abstract:
8032 | Poster
Molecular Profiling across Histologies in Lung Cancer: Time to change WHO nomenclature?
First author:
Alessandro Russo
Collaborating Institution:
Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
DO:
Lung
Abstract:
8532 | Poster
FGFR3 Mutated (FGFR3mut+) Urothelial Carcinoma of Bladder (UCB) and Upper Tract (UTUC) Including Ureter (UUC) and Renal Pelvis (RPUC): a Comparative Genomic Profiling Study
First author:
M Basin
Collaborating Institution:
Foundation Medicine, Inc.
DO:
Bladder
Abstract:
4588 | Poster
On the Right TRACK: Operationalizing a National, Patient-Centric Fully Remote Precision Trial Offering Comprehensive Genomic Profiling and a Molecular Tumor Board for Rare Cancers
First author:
Jim Palma
Collaborating Institution:
TargetCancer Foundation, Cambridge, Massachusetts, USA
DO:
Multi-tumor
Abstract
3127 | Poster
Contrasting Comprehensive Genomic Profiles (CGP) of Adenocarcinomas of the Appendix (AAC) in Young verses Older patients
First author:
Myera Shahnawaz
Collaborating Institution:
Foundation Medicine, Inc.
DO:
Appendix
Abstract:
3626 | Poster
Intimal Sarcomas (ISarc) of the Cardiac Chambers (CC) of the Heart and Great Vessels (GV): A Comprehensive Genomic Profiling (CGP) Study
First author:
Maroun Bou Zerdan
Collaborating Institution:
Foundation Medicine, Inc.
DO:
Heart
Abstract:
11575 | Poster
Impact of alterations in Tumor Suppressor Genes (TSG-alt) on Survival Outcomes in patients (pts) with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC) receiving intensified androgen deprivation therapy (ADTi).
First author:
Arshit Narang
Institution:
Foundation Medicine, Inc.
DO:
Prostate
Abstract:
5091 | Poster
Outcomes and clinical, molecular, and immune profiling of head and neck squamous cell carcinoma (HNSCC) brain metastases (BM)
First author:
Michael Dennis
Collaborating Institution:
Dana-Farber Cancer Institute
DO:
Head and neck
Abstract:
6036 | Poster
New soft tissue sarcoma (STS) transcriptomic clusters unveil STS subsets with unique biological characteristics and refine the accuracy of overall survival (OS) prediction
First author:
Miguel Esperanca-Martins
Collaborating Institution:
Medical Oncology Department, Centro Hospitalar Universitario Lisboa Norte, Lisboa, Portugal
DO:
Sarcoma
Abstract:
11545 | Poster
Genetic ancestry-associated differences in genomic profiling and treatment patterns in pancreatic ductal adenocarcinoma (PDAC)
First author:
Jacquelyne Gaddy
Collaborating Institution:
Yale Cancer Center, New Haven, CT, USA
DO:
Pancreatic
Abstract:
4138 | Poster
The Landscape of Genomic Biomarkers, Ancestry, and Real-World Outcomes in ERBB2 Amplified Endometrial Carcinoma (EC)
First author:
Thomas Herzog
Collaborating Institution:
Foundation Medicine, Inc.
DO:
Endometrial
Abstract:
5614 | Poster
FoundationOne®CDx and FoundationOne®Liquid CDx are qualitative next-generation sequencing based in vitro diagnostic tests for advanced cancer patients with solid tumors and are for prescription use only. FoundationOne CDx utilizes FFPE tissue and analyzes 324 genes as well as genomic signatures. FoundationOne Liquid CDx analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes. The tests are companion diagnostics to identify patients who may benefit from treatment with specific therapies in accordance with the therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the tests does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy for testing with FoundationOne CDx when archival tissue is not available which may pose a risk. Patients being considered for eligibility for therapy based on detection of NTRK1/2/3 and ROS1 fusions should only be tested if tissue is unavailable. Patients who are tested with FoundationOne Liquid CDx and are negative for other companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com and www.F1LCDxLabel.com.
*Based on genomic testing guidelines in advanced breast cancer. Does not include germline or IHC testing.
**Based on somatic testing guidelines in advanced prostate cancer, including 19 HRR genes, MSI/MSI-H, plus 7 clinically relevant biomarkers (TMB, MSH2, MSH6, PMS2, PTEN, RB1, TP53).
*** Data on File, Foundation Medicine, Inc., October 2023.
†Research use only.
1. Data on File, Foundation Medicine, Inc., 2024
2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V4.2023. © 2023 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed February 12, 2024. To view the most recent and complete version of the guidelines, go online to NCCN.org.
3. FoundationOne Liquid CDx Technical Specifications (Gene List). https://www.foundationmedicine.com/sites/default/files/media/documents/2023-10/F1LCDx_Technical_Specs_072021-2.pdf. Accessed February 13, 2024.
4. FoundationOne CDx Technical Specifications (Gene List). https://www.foundationmedicine.com/sites/default/files/media/documents/2024-01/F1CDx%20Technical%20Specifications%20SPEC-01197.pdf. Accessed February 13, 2024.
5. Data on File, Foundation Medicine, Inc., August 2023.